Novel myd88 inhibitor for treatment of autoimmune diseases and uses thereof
A peptide targeting the MyD88 TIR domain, combined with a cell-penetrating peptide, addresses the lack of MyD88-targeting treatments by inhibiting MyD88 signaling, demonstrating efficacy in reducing inflammation and treating autoimmune and inflammatory diseases.
Patent Information
- Application Number
- PCT/KR2024/006955
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
Current treatments for autoimmune diseases, inflammatory diseases, and neurodegenerative diseases lack effective MyD88-targeting drugs, as MyD88 plays a central role in TLR and IL-1R signaling pathways but no MyD88-targeting drugs are approved for clinical use.
Development of a peptide that inhibits MyD88 signaling by targeting the MyD88 TIR domain, combined with a cell-penetrating peptide to enhance cellular uptake, forming a MyD88 inhibitor for use in pharmaceutical and cosmetic compositions to treat MyD88-related diseases.
The peptide effectively inhibits MyD88-dependent signaling, reducing pro-inflammatory cytokine production and showing therapeutic potential in models of psoriasis and experimental autoimmune encephalomyelitis, offering a promising strategy for treating autoimmune and inflammatory diseases.
Smart Images

Figure KR2024006955_28112024_PF_FP_ABST
Abstract
Description
Novel MYD88 inhibitors and their uses for the treatment of autoimmune diseases
[0001] The present invention relates to a peptide that inhibits the MyD88 (Myeloid differentiation primary-response 88) signaling pathway, and more particularly, to a peptide that inhibits the MyD88 signaling pathway by targeting the TIR (Toll / interleukin-1 receptor) domain of MyD88, a fusion peptide in which the peptide and a cell-penetrating peptide (CPP) are combined, a MyD88 inhibitor comprising the peptide or fusion peptide, and a pharmaceutical composition and cosmetic composition for preventing or treating MyD88-related autoimmune diseases, inflammatory diseases, or neurodegenerative diseases.
[0002]
[0003] Toll-like receptor (TLR) signaling is crucial for innate immune defense against external agents (Xiaopei Huang and Yiping Yang, Expert Opin Ther Targets. 2010 Aug; 14(8): 787-796). TLRs are the most extensively studied pattern recognition receptors (PRRs) that can activate a variety of cells, including both immune and non-immune cells. Their downstream signaling pathways generate a broad spectrum of immunostimulatory cytokines and chemokines (Ji-Qing Chen, et al., Clinical Reviews in Allergy & Immunology, 2016 Feb; 50(1): 1-17). However, excessive TLR activation impairs immune homeostasis due to the sustained production of pro-inflammatory cytokines, chemokines, and interferons, contributing to the development of numerous inflammatory and autoimmune diseases (Wei Gao, et al., Front Physiol.2017 Jul 19;8:508; Li Chen, et al., Acta Pharmacologica Sinica.2021 Nov;42(11):1742-1756).
[0004] Myeloid differentiation primary-response 88 (MyD88) is a canonical adaptor protein that links the interleukin-1 receptor (IL-1R) and TLRs to IL-1R-associated kinase (IRAK) through homotypic protein-protein interactions (Jacques Deguine and Gregory M. Barton, F1000Prime Rep2014, 6:97). MyD88 serves as a crucial adaptor for IL-1 / Toll receptor superfamily signaling. After IL-1R or TLR stimulation, MyD88 is recruited to the activated receptor complex and forms a complex with IRAK4 to activate IRAK1. This activates tumor necrosis factor-associated factor 6, which leads to the phosphorylation of IKK (Iκkinase) and the activation of NF-κF kappa light chain enhancer of activated B cells (O Landgren, N Tageja, Leukemia. 2014 Sep; 28(9): 1799-803). Therefore, MyD88 serves as a central protein in the TLR signaling pathway, functioning as a master switch in various inflammatory diseases. Although MyD88 is considered an important therapeutic target, there are currently no MyD88-targeting drugs approved for clinical use (Jiali Song, et al., Front Pharmacol. 2021 Nov 29; 12: 775-117).
[0005] MyD88 is a 31–33 kDa adaptor protein with a death domain (DD) at the amino terminus and a TIR domain at the C terminus. These two domains are separated by a short linker region, also called the intermediate domain (ID) (Mark A Olson, et al., Sci Rep. 2015 Sep 18; 5:14246). MyD88 interacts with IRAK1, IRAK2, IRAK4, and IRAK-M through the DD (Su-Chang Lin, et al., Nature. 2010 Jun 17; 465(7300): 885-90). MyD88 is involved in signal transduction initiated by all TLRs except TLR3 (Jacques Deguine and Gregory M. Barton, F1000Prime Rep. 2014, 6:97). Recent crystallographic investigation studies have shown that MyD88 TIR (MyD88 TIR ) was observed to form a higher-order assembly consisting of two parallel strands of TIR domains arranged head-to-tail with the subunits constituting each strand (Max TB Clabbers, et al., Nat Commun. 2021 May 10;12(1):2578). MyD88 TIR During the nucleation and elongation stages of assembly formation, MyD88 is introduced TIR The molecule is MAL TIR MyD88 at the BB surface (BB loop site) or EE surface (αE helix site) of (MyD88 adaptor-like protein TIR) TIR Binding to the subunit; interstrand interactions through the BC (αB and αC helices) and CD (CD loop and αD helix region) surfaces induce conformational changes in the αB helix and BB loop of the TIR domain molecule, which induces the incoming MyD88 TIRIt allows interaction with the EE surface of the subunit. MAL-induced MyD88 in solution TIR Microcrystal formation was found to be disrupted by alanine substitutions at the intrastrand interface of R196, D197, P200, W284 and R288 and at the inter-strand interface of K238, L241, S266 and R269 (Thomas Ve, et al., Nat Struct Mol Biol. 2017 Sep;24(9):743-751). Furthermore, intrastrand mutations R196A, W284A, I253D, and R288A were shown to interfere with TLR4 ligand lipopolysaccharide (LPS)-induced NF-κB activation, while P200A in the B loop significantly reduced activation (Max TB Clabbers, et al., Nat Commun. 2021 May 10;12(1):2578). Activation of TLRs, which are MyD88-dependent receptors in the central nervous system (CNS), has been implicated in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE) (Chao Zheng, et al., Front Mol Neurosci. 2020 Jan 10;12:314). TLR activation in the CNS induces the production of proinflammatory cytokines and chemokines that contribute to the demyelination and neurodegeneration seen in MS and EAE.
[0006] MS is the most common non-traumatic disorder in young adults, and is characterized by central nervous system (CNS) lesions due to perivascular immune cell infiltration and destruction of myelin, oligodendrocytes, and neurons (Socorro Miranda-Hernandez, Alan G Baxter, Am J Clin Exp Immunol. 2013 Feb 27;2(1):75-93). It occurs in young adults with a complex genetic makeup and can also be triggered by inflammatory environmental insults such as viral infections (R Dobson, G Giovannoni, Eur J Neurol. 2019 Jan;26(1):27-40). CD4 + (cluster of differentiation 4 + ) Activation of autoreactive T cells and their development into a Th1 (T helper 1) phenotype are important processes in the early stages of the disease. These cells are likely to play a significant role in the long-term progression. Damage to the target tissue, the CNS, is mediated by antibodies, complement, and CD8 + It can be mediated by other immune system components such as T cells and innate immune cell-produced proteins, Th2 cells, regulatory CD4 +Alterations in the immune regulatory network, including T cells and natural killer (NK) cells, may contribute to the relapsing-remitting or chronic progressive nature of the disease (Mireia Sospedra, Roland Martin, Annu Rev Immunol. 2005;23:683-747). The experimental model used for MS is EAE, a complex disorder in which a combination of numerous immunopathological and neuropathological mechanisms resemble the core pathological features of MS: inflammation, demyelination, axonal loss, and gliosis (Cris S Constantinescu, et al., Br J Pharmacol. 2011 Oct;164(4):1079-106). The role of TLRs in MS and EAE has been extensively studied (Chao Zheng, et al., Front Mol Neurosci. 2020 Jan 10;12:314).
[0007] Several autoimmune and autoinflammatory disorders, including psoriasis, are associated with the activation of nucleic acid-sensing TLRs by self-nucleic acids (Nicholas A Lind, et al., Nature Reviews Immunology, 2022 Apr; 22(4): 224-235). Psoriasis is a widespread, chronic inflammatory skin disease characterized by increased cell proliferation, altered epidermal differentiation, and inflammatory cell infiltration, the pathogenesis of which depends on genetic predisposition and environmental factors (Philipp Novoszel, et al., EMBO Mol Med, 2021 Apr 9; 13(4): e12409). Psoriasis is considered a T-cell-mediated disease because T-cell-derived cytokines, such as IL-17A and IL-22, induce keratinocyte hyperproliferation and abnormal differentiation, leading to the formation of psoriatic plaques. Nonetheless, pattern recognition receptor (PRR)-mediated recognition of danger-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) and the innate immune response of keratinocytes or plasmacytoid dendritic cells (pDCs) are considered early initiating events in psoriasis that promote adaptive and autoimmune responses. Keratinocytes can produce proinflammatory cytokines to initiate an inflammatory T cell phenotype in psoriasis after DAMP or PAMP stimulation. Targeting PRR-mediated innate immune activation of keratinocytes or pDCs in combination with T cell treatment may be an effective therapeutic option for psoriasis (Lixiang Sun, et al., J Immunol Res. 2019 Nov 14;2019:1824624).The role of TLRs in psoriasis has been studied, and anti-IL-12 / IL-23 agents as well as antagonists of TLR7 and TLR8 have shown potential in the treatment of psoriasis (Farzaneh Rahmani, Nima Rezaei Rahmani, Expert Rev Clin Immunol. 2016 Dec; 12(12): 1289-1298). Inhibition of MyD88 has been shown to attenuate imiquimod (IMQ)-induced skin inflammation (Hanitriniaina Rabeony, et al., Eur J Immunol. 2015 Oct; 45(10): 2847-57).
[0008] In the present invention, we aimed to develop a novel peptide that targets the MyD88 TIR domain and inhibits MyD88-mediated signaling. To achieve this, we designed a novel peptide and fused it to a cell-penetrating peptide called penetratin to enhance cellular uptake. The efficacy of the resulting peptide was evaluated for its ability to inhibit MyD88-dependent signaling in mouse and human macrophages, as well as its ability to suppress TLR- and IL-1R-induced cytokine activation. Subsequently, we evaluated the therapeutic potential of the most potent peptide in both IMQ-induced psoriasis models and EAE, and investigated its mechanism of action. These results demonstrate that the rationally designed peptide is a potent inhibitor of MyD88-mediated signaling, thereby offering a promising strategy for the development of therapeutics for autoimmune diseases.
[0009]
[0010] The above information described in this background section is solely intended to enhance understanding of the background of the present invention and may not include information that constitutes prior art already known to a person of ordinary skill in the art to which the present invention pertains.
[0011]
[0012] Summary of the invention
[0013] The purpose of the present invention is to provide a peptide having the function of inhibiting the MyD88 signaling pathway.
[0014] Another object of the present invention is to provide a fusion peptide in which the peptide and a cell-penetrating peptide (CPP) are combined.
[0015] Another object of the present invention is to provide a MyD88 inhibitor comprising the peptide or fusion peptide.
[0016] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating MyD88-related autoimmune diseases, inflammatory diseases, or neurodegenerative diseases, comprising the peptide or fusion peptide.
[0017] Another object of the present invention is to provide a method for preventing or treating MyD88-related autoimmune diseases, inflammatory diseases or neurodegenerative diseases using the peptide or fusion peptide, a use of the peptide or fusion peptide for preventing or treating MyD88-related autoimmune diseases, inflammatory diseases or neurodegenerative diseases, and a use of the peptide or fusion peptide for manufacturing a medicament for preventing or treating MyD88-related autoimmune diseases, inflammatory diseases or neurodegenerative diseases.
[0018] Another object of the present invention is to provide a cosmetic composition for preventing or improving MyD88-related autoimmune diseases, inflammatory diseases, or neurodegenerative diseases, comprising the peptide or fusion peptide.
[0019]
[0020] To achieve the above purpose, the present invention provides a peptide represented by any one amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 11.
[0021] The present invention also provides a fusion peptide in which the peptide and a cell-penetrating peptide (CPP) are combined.
[0022] The present invention also provides a MyD88 inhibitor comprising the peptide or fusion peptide.
[0023] The present invention also provides a pharmaceutical composition for preventing or treating MyD88-related autoimmune diseases, inflammatory diseases, or neurodegenerative diseases, comprising the peptide or fusion peptide.
[0024] The present invention also provides a method for preventing or treating MyD88-related autoimmune diseases, inflammatory diseases, or neurodegenerative diseases, comprising a step of administering the peptide or fusion peptide.
[0025] The present invention also provides the use of the peptide or fusion peptide for the prevention or treatment of MyD88-associated autoimmune diseases, inflammatory diseases or neurodegenerative diseases.
[0026] The present invention also provides the use of the peptide or fusion peptide for the manufacture of a medicament for the prevention or treatment of MyD88-related autoimmune diseases, inflammatory diseases or neurodegenerative diseases.
[0027] The present invention also provides a cosmetic composition for preventing or improving MyD88-related autoimmune diseases, inflammatory diseases, or neurodegenerative diseases, comprising the peptide or fusion peptide.
[0028]
[0029] Figure 1 is a schematic diagram illustrating the computer design of a MyD88 inhibitory peptide. (a) A schematic diagram of an assembly model of MyD88 highlighting the specific region targeted by the peptide design. The Toll / interleukin-1 receptor (TIR) domain of MyD88 oligomerizes to form a signaling complex, which triggers downstream pathways leading to proinflammatory cytokine production. (bg) MyD88 TIR Specific regions of the domain interface were identified for computational design of inhibitory peptides. These regions include the αE helix (b), the DD loop (c), the βE+EE loop (d), the αC helix (e), the αC' helix (f), and the BB loop (g), from which MyDIP2-4 is derived. The designed peptides were designed to inhibit MyD88 signaling and thereby prevent the production of proinflammatory cytokines.
[0030] Figure 2 is a schematic diagram illustrating the screening and identification of potential MyD88 inhibitory peptides. (a and b) Graphs showing the quantification of TNF-α and IL-6 secreted by mouse macrophages pretreated with the indicated concentrations of peptides and stimulated with LPS (100 ng / mL). (c) Graph showing the cell viability analysis (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT) of mouse macrophages treated with the indicated concentrations of candidate peptides. (d) The inhibitory effect of MyDIP2 on the MyD88-mediated signaling pathway was evaluated by measuring TNF-α levels in RAW 264.7 cells by ELISA. The cells were pretreated with MyDIP2 peptide at concentrations of 1, 10, and 50 μM and then activated with various concentrations of Pam3CSK4 (acting on TLR2 / 1), FSL-1 (TLR2 / 6), poly(I:C) (TLR3), flagellin (Flg, TLR5), imiquimod (IMQ, TLR7), R848 (TLR7 / 8), TL8 (TLR8), or CpG oligodeoxynucleotide (CpG-ODN, acting on TLR9). The results are expressed as Mean ± SD. *p < 0.33, **p < 0.002, ***p < 0.001. MTT is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; mTNF-α is mouse tumor necrosis factor alpha; mIL-6 is mouse interleukin-6; LPS is liposaccharide; NF-κB is nuclear factor kappa B; MAPK is mitogen-activated protein kinase; IC 50 is half-maximal inhibitory concentration; IMQ is imiquimod.
[0031] Figure 3 is a diagram illustrating the selection of optimal peptides among derivatives. (a) A graph showing the results of cell viability analysis using the MTT assay after treatment with 50 μM of candidate peptides. (b) A graph showing the level of TNF-α secretion after pretreatment with 20 μM peptides and treatment with LPS (100 ng / ml). (c) A graph showing the dose-dependent effect of MyDIP2-4 on LPS-induced TNF-α secretion. (d) IC 50 Graph. (e) Graph showing the effect of MyDIP2-4 on LPS-induced IL-6 secretion. (f) Western blot analysis of IMQ-induced secretion of NF-κβ and MAPKs after MyDIP2-4 treatment. RAW 264.7 cells were treated with MyDIP2-4 in the presence or absence of 2 μg / ml IMQ. Western blot analysis of p-ERK, T-ERK, JNK, p-JNK, pp-38, pp-65, and Iκβα, with β-actin serving as a loading control. (g) The dose-dependent effects of MyDIP2-4 on various concentrations of TLR ligands Pam3CSK4 (TLR1 / 2), FSL-1 (TLR2 / 6), poly(I:C) (TLR3), flagellin (TLR5), resiquimod (R848, TLR7 / 8), TL8 (TLR8), or CpG-ODN (TLR9) are shown in the graph. Results are expressed as Mean ± SD. *p < 0.33, **p < 0.002, ***p < 0.001. MTT is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TNF-α is tumor necrosis factor alpha; LPS is liposaccharide; NF-κβ is nuclear factor kappa B; MAPKs are mitogen-activated protein kinases; IC 50is half-maximal inhibitory concentration; IMQ is imiquimod.
[0032] Figure 4 TLR-mediated activation of human macrophages, MOG 35-55 (Myelin oligodendrocyte glycoprotein peptide fragment 35-55)-induced EAE and the effect of MyDIP2-4 on the biophysical interaction between MyDIP2-4 and MyD88 proteins. (a) Graph showing the effect of 20 μM MyDIP2 and MyDIP2-4 on the viability of THP-1-derived macrophages determined using the MTT assay. (b, c) Graph showing the secretion of the cytokine TNF-α measured using ELISA to evaluate the dose-dependent inhibition by MyDIP2 and MyDIP2-4, respectively, in response to TLR4 stimulation by LPS (100 ng / ml). (d) THP-1-derived macrophages were pretreated with MyDIP2-4 peptide and stimulated with IL-1β (150 ng / ml). TNF-α secretion was assessed using ELISA analysis. (e) Graph showing the secretion of IL-1β in response to NLRP3 (NACHT, LRR, and PYD domains-containing protein 3) activation in the presence and absence of MyDIP2-4. (f) Schematic of the interaction between MyDIP2-4 and MyD88 protein. The sensorgram depicts the binding of MyDIP2-4 to MyD88 protein in a dose-dependent manner. The sensorgram shows real-time changes in response units over time, indicating the strength and kinetics of the MyDIP2-4-MyD88 interaction. (g) To test the therapeutic potential of MyDIP2-4 in the progression of EAE, mice were treated with MOG in complete Freund's adjuvant (CFA). 35-55Mice were vaccinated with peptide and administered pertussis toxin twice, once on day 0 and again 24 hours later. (h) Clinical scores were calculated according to the protocol provided by the kit manufacturer. (i) Body weights of mice in each group were measured on the indicated dates. The graph shows the results of ELISA performed to measure (j) IL-17, (k) TNF-α, (l) IFN-γ, and (m) IL-6 levels in plasma samples separated from blood by centrifugation at 3000 RPM. Results are expressed as Mean ± SD. *p < 0.33, **p < 0.002, ***p < 0.001. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TLR, Toll-like receptor; TNF-α, tumor necrosis factor alpha; LPS, liposaccharide; IL, interleukin; ELISA is enzyme-linked immunosorbent assay; MOG is myelin oligodendrocyte glycoprotein.
[0033] Figure 5 shows the effect of MyDIP2-4 on IMQ-induced psoriasis. (a) Psoriasis was induced by topical application of 5% IMQ to the shaved backs of C57BL / 6 mice. Dexamethasone (10 mg / kg) was selected as a positive control. The therapeutic effect of MyDIP2-4 was evaluated at two doses, 5 mg / kg and 20 mg / kg. Mice were euthanized on day 6 and further experiments were performed. (b) Photograph of the backs of mice on the last day before euthanasia. (c) Graph showing the PASI scores of drug-treated and IMQ-treated mice to assess disease severity. (d) Graph showing the effect of MyDIP2-4 and dexamethasone on body weight in IMQ-induced psoriasis mice. (e) H&E staining of the epidermis to assess the degree of epidermal invasion in the different groups. (f) Immunohistochemical analysis of KI-67, IL-23, and IL-17 expression in skin tissue. Results are presented as Mean ± SD. *p < 0.33, **p < 0.002, ***p < 0.001. IMQ is imiquimod; PASI is psoriasis area and severity index; H&E is hematoxylin and eosin.
[0034]
[0035] Detailed description of the invention and preferred embodiments
[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Generally, the nomenclature used herein is well known and commonly used in the art.
[0037]
[0038] MyD88 is called one of the pillars of immunology. MyD88 is a ubiquitously expressed cytoplasmic adaptor protein that plays a pivotal role in the TLR and IL-1R signaling pathways. The TLR / IL-1R pathway regulates the proliferation and development of innate and adaptive immune system cells (Lingfeng Chen, et al., J Med Chem. 2020 Nov 25;63(22):13316-13329). Due to its central role in various immune response pathways, MyD88 is an attractive target for controlling immune responses in various diseases, including autoimmune diseases (Jiali Song, et al., Front Pharmacol. 2021 Nov 29;12:775-117). The TIR domain of MyD88 plays a crucial role in recruiting various signaling proteins and initiating downstream signaling cascades.
[0039] Development of MyD88 interface-binding peptides provides a promising approach to modulate MyD88-mediated signaling by specifically targeting protein-protein interactions at the MyD88 interface, thereby inhibiting downstream signaling and reducing inflammation and other disease symptoms. Designing peptides targeting the TIR domain of MyD88 can effectively inhibit MyD88-dependent signaling in TLR- and IL-1R-mediated signaling pathways, making them important potential therapeutic targets for autoimmune diseases. Using the PyRosetta program (Chaudhury, S. et al., Bioinformatics 2010 Mar 1;26(5):689), we generated peptides targeting the MyD88 interaction interface and evaluated the efficacy of the MyDIP2-4 peptides in inhibiting TLR and IL-1R signaling in mouse and human macrophages. Although MyD88 is not involved in TLR3 signaling, the fact that the TIR domain of MyD88 is also present in TRIF (TIR-domain-containing adapter-inducing interferon-β) explains the peptide's effect on TLR3-mediated TNF-α, as the peptide was designed to target the TIR domain. The Ka and Kd values obtained from surface plasmon resonance (SPR) analysis indicate that MyDIP2-4 strongly interacts with MyD88 (Fig. 4f), with an IC of 2.6 μM. 50 The values are promising compared to other available MyD88-inhibiting peptides (Shira Dishon, et al., Sci Rep. 2018 Jun 21;8(1):9476).
[0040] The relationship between MyD88 and NLRP3 has long been debated. Recently, studies have shown that NLRP3 inflammasome activation inhibits TLR signaling and cytokine production induced by agents or infections through caspase-1 proteolytic cleavage of MyD88 (Monika Avbelj et al., Front Immunol. 2022 Jan 5;12:790-258). NLRP3 is downregulated by MyD88 inhibition, but MyD88 inhibition has not been shown to directly inhibit NLRP3-mediated IL-1β secretion (Vivek Verma et al., Scand J Immunol. 2021;94:e13104). This study is consistent with our results, in which the MyDIP2-4 peptide did not exert its effect when NLRP3 was activated by nigericin (Fig. 4e).
[0041] Inhibition of MyD88-mediated signaling may have therapeutic benefits for diseases such as psoriasis, an inflammatory skin disease involving both the innate and adaptive immune systems. The pathophysiology of psoriasis is complex. Despite the clinical efficacy of etanercept, a TNF-α blocker, in the treatment of psoriasis, treatment remains a significant challenge. The PASI score is based on the degree and area of erythema, induration, and desquamation of plaques in other parts of the body.
[0042] The pathophysiology of psoriasis involves dendritic cell activation, and IL-23 is required for disease progression (Tom C Chan et al., Ther Adv Chronic Dis. 2018 May; 9(5): 111-119). High levels of IL-23 are associated with erythema, mixed inflammatory infiltrates, and epidermal proliferation (Leslie van der Fits et al., The Journal of Immunology. 2009 May 1; 182(9): 5836-45). We aimed to investigate the effects of MyDIP2-4 in a psoriasis model. Immunohistochemical analysis revealed that both doses of MyDIP2-4 significantly reduced IL-23 levels in skin tissue (Fig. 5f), consistent with previous findings (Fenli Shao et al., Biochem Pharmacol. 2016 Sep 1; 115: 94-103).
[0043] IL-23 plays a crucial role in the pathogenesis of psoriasis by stimulating the production of IL-17 from γδT cells. Subsequent signaling via IL-17 is associated with the development of neutrophilic microabscesses, hyperproliferation, and attenuation of keratinocyte differentiation, resulting in epidermal hyperplasia at the site of injury (Hye-Lin Ha et al., Proc Natl Acad Sci US A. 2014 Aug 19;111(33):E3422-31). MyDIP2-4 significantly reduced IL-23 levels, but did not alter IL-17 levels in skin tissue (Fig. 5f). These results may be due to the fact that IL-17 production can be either IL-23 dependent or independent, as previously reported in the literature (Y Yoshiga, et al., Int J Mol Med. 2008 Sep;22(3):369-74.).
[0044] IL-17 has been demonstrated to upregulate KI-67, a well-established marker of cell proliferation that correlates with the clinical severity of psoriasis and is upregulated in psoriatic skin lesions (Hanna Niehues, et al., JID Innov. 2021 Oct 22;2(1):100066) (Y Luo, et al., Clin Exp Immunol. 2020 Oct;202(1):1-10). Although IL-17 was not downregulated, KI-67 was significantly downregulated in MyDIP2-4-treated mouse skin tissues compared to IMQ-treated mouse tissues. MyD88 expression was positively correlated with high KI-67 expression (Jing Niu, et al., Mol Med Rep. 2020 Aug;22(2):1243-1256), demonstrating that MyDIP2-4 downregulated MyD88 expression and thereby reduced KI-67 expression. Notably, MyDIP2-4 treatment did not significantly reduce epidermal invasiveness (Fig. 5f), which is consistent with the results of a study by Costa et al. (Sara Costa, et al., J Leukoc Biol. 2017 Sep;102(3):791-803).
[0045] MS is a chronic neuroautoimmune and neurodegenerative disease that causes central nervous system (CNS) inflammation, demyelination, and axonal and neuronal cell death. EAE is a widely used animal model for MS research (Cris S Constantinescu, et al., Br J Pharmacol. 2011 Oct;164(4):1079-106). EAE is induced by injecting components of the immune system that induce an immune response against the myelin sheath of test animals. This results in neurological symptoms similar to those observed in MS patients. However, the exact cause of MS is still not fully understood (Bert A 't Hart, et al., EBioMedicine. 2021 Jun;68:103-392). Although the causative agents of MS and EAE may be different, the EAE model has provided important information about the basic mechanisms of MS and is being used to develop and test new treatments for the disease (Andrew P Robinson, et al., Handb Clin Neurol. 2014;122:173-89).
[0046] The therapeutic efficacy of targeting MyD88 for the treatment of EAE is currently a topic of interest. One study showed that treatment with a MyD88 inhibitor reduced proinflammatory cytokine production and alleviated EAE symptoms in mice (Shira Dishon, et al., Front Immunol. 2017 May 29;8:615).
[0047]
[0048] Accordingly, the present invention relates, in one aspect, to a peptide represented by any one amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 11.
[0049] As used herein, the term "peptide" refers to a linear molecule formed by amino acid residues linked together by peptide bonds. The peptide can be prepared using chemical synthesis methods known in the art.
[0050] The above peptide is a peptide targeting the interaction interface of MyD88, and is defined herein as MyDIP. The amino acid sequences of MyDIP1 to MyDIP7 and derivatives of MyDIP2, MyDIP2-1 to MyDIP2-4, are as follows:
[0051] MyDIP1: WFWTRLAKA (SEQ ID NO: 1)
[0052] MyDIP2: WFWTRLAKALSLP (SEQ ID NO: 2)
[0053] MyDIP3: KYKAMKKE (SEQ ID NO: 3)
[0054] MyDIP4: DYTNPCTKS (SEQ ID NO: 4)
[0055] MyDIP5: SDDYLQSK (SEQ ID NO: 5)
[0056] MyDIP6: ECDFQTMFALSL (SEQ ID NO: 6)
[0057] MyDIP7: SDRDVLPGTCVWSIA (SEQ ID NO: 7)
[0058] MyDIP2-1: WFWYRLAKKLSLP (SEQ ID NO: 8)
[0059] MyDIP2-2: WFWYRLIKKLSLP (SEQ ID NO: 9)
[0060] MyDIP2-3: WFWYILLKKLSLP (SEQ ID NO: 10)
[0061] MyDIP2-4: WLWFILFKKLSLP (SEQ ID NO: 11)
[0062] The peptide according to the present invention is interpreted to mean also including variants or fragments thereof in which amino acid residues are conservatively substituted at specific amino acid residue positions.
[0063] As used herein, “conservative substitution” means a modification that involves replacing one or more amino acids with amino acids having similar biochemical properties that do not result in loss of biological or biochemical function of the peptide.
[0064] A "conservative amino acid substitution" is a substitution that replaces an amino acid residue with an amino acid residue having a similar side chain. Classes of amino acid residues with similar side chains are well-defined and known in the art. These classes include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with beta-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0065] It is expected that the MyDIP1 to MyDIP7 and MyDIP2-1 to MyDIP2-4 peptides of the present invention may still retain activity even if they have conservative amino acid substitutions.
[0066] The peptide according to the present invention may be interpreted to mean a peptide having substantially the same function and / or effect as the above peptide, and having an amino acid sequence homology of 80% or 85% or more, preferably 90% or more, more preferably 95% or more, and most preferably 99% or more with the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 11, but is not limited thereto.
[0067] In the present invention, the peptide may be characterized by inhibiting MyD88-mediated signaling and thereby inhibiting TLR and IL-1R-mediated signaling pathways.
[0068] As used herein, the term "TLR-mediated signaling pathway" refers to a signaling pathway through TLR, which may be a reaction dependent on a complex formed by TLR and the adaptor protein MyD88 or TLR and the adaptor protein TRIF (in the case of TLR3), through which a signal is transmitted. Activated TLR activates NF-κB through a MyD88-dependent signaling process, causing it to translocate to the nucleus and induce the activation of MAPK. The activation of NF-κB and MAPK causes the secretion of proinflammatory cytokines such as TNF-α and IL-6.
[0069] In the present invention, the term "TIR domain" is a domain for intracellular signaling, has three highly conserved regions, and mediates interactions between TLRs and other signaling molecules.
[0070]
[0071] From another perspective, the present invention relates to a fusion peptide in which the peptide and a cell-penetrating peptide (CPP) are combined.
[0072] In the present invention, the term “cell-penetrating peptide (CPP)” is a type of signal peptide, which is a peptide that is a combination of a specific amino acid sequence used for the purpose of delivering high molecular substances such as proteins, DNA, and RNA into cells. To date, it has been used for the intracellular delivery of various low molecular weight compounds, proteins, peptides, RNA, and high molecular substances such as DNA. Most cell-penetrating peptides are derived from protein transduction domains (PTDs) or membrane translocating sequences, and unlike general routes of entry of external substances into cells, they are expected to play a groundbreaking role in moving into cells without damaging the cell membrane, and even delivering DNA and proteins, which are known to be unable to pass through the cell membrane, into cells.
[0073] The fusion peptide of the present invention utilizes a cell-penetrating peptide. The cell-penetrating peptide is not particularly limited as long as it has the characteristic of entering a cell through a cell internalization (endocytosis) mechanism, but is preferably selected from the group consisting of cell-penetrating peptides or variants thereof listed in Table 1 below.
[0074]
[0075]
[0076] In one embodiment of the present invention, an experiment was conducted by selecting Penetratin represented by the amino acid sequence of SEQ ID NO: 12, and it will be apparent to those skilled in the art that even when a cell-penetrating peptide other than the cell-penetrating peptide actually used is fused with the peptide of the present invention, an effect similar to that of the present invention is exhibited.
[0077] In the present invention, the peptide and the cell-penetrating peptide may be characterized in that they are connected directly or through a linker.
[0078]
[0079] In one embodiment of the present invention, a peptide represented by any one amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 11 exhibited an effect of inhibiting MyD88-dependent signaling and an effect of inhibiting TLR- and IL-1R-induced cytokine activation.
[0080] Accordingly, the present invention, in another aspect, relates to a MyD88 inhibitor comprising the peptide or the fusion peptide.
[0081] As used herein, the term “inhibitor” refers to a molecule that partially or completely inhibits the effect of another molecule, such as a receptor or an intracellular mediator, through any mechanism. As used herein, “inhibitor” is used with the same meaning as “antagonist” or “inhibitor,” and the term “inhibition” refers to a phenomenon in which biological activity or signaling activity is reduced due to deficiency, imbalance, or many other causes, and may partially or completely block, reduce, prevent, delay activation, inactivate, or downregulate the activity of MyD88.
[0082] In the present invention, the term “MyD88 inhibitor” means a substance that can directly or indirectly, or substantially, interfere with, reduce or inhibit the biological activity of MyD88.
[0083]
[0084] According to one embodiment of the present invention, the peptide inhibits the secretion of proinflammatory cytokines associated with MyD88 signaling, and thus can be usefully utilized as a composition for preventing or treating MyD88-related diseases.
[0085] Therefore, the present invention, from another aspect, relates to a pharmaceutical composition for preventing or treating a MyD88-related disease comprising the peptide or the fusion peptide.
[0086] In another aspect, the present invention relates to a method for preventing or treating a MyD88-related disease, comprising administering the peptide or the fusion peptide.
[0087] In another aspect, the present invention relates to the use of the peptide or the fusion peptide for the prevention or treatment of MyD88-related diseases.
[0088] In another aspect, the present invention relates to the use of the peptide or the fusion peptide for the manufacture of a medicament for the prevention or treatment of MyD88-related inflammatory diseases.
[0089]
[0090] In the present invention, the MyD88-related disease is an abnormal disease caused by abnormal activation of MyD88, and may be characterized as being preferably an autoimmune disease, an inflammatory disease, or a neurodegenerative disease, but is not limited thereto.
[0091] As used herein, the term "autoimmune disease" refers to a disease caused by a process in which a problem occurs in inducing or maintaining self-tolerance, resulting in an immune response to self-antigens, which in turn leads to an attack on one's own tissues. Self-tolerance refers to immunological unresponsiveness, in which the body does not react harmfully to antigenic substances that constitute the self. The autoimmune disease of the present invention may include, but is not limited to, psoriasis, rheumatoid arthritis, psoriatic arthritis, experimental autoimmune arthritis, asthma, Crohn's disease, multiple sclerosis, experimental autoimmune encephalomyelitis, myasthenia gravis, thyroiditis, experimental uveitis, Hashimoto's thyroiditis, primary myxedema, thyrotoxicosis, pernicious anemia, autoimmune atrophic gastritis, Addison's disease, premature menopause, male infertility, juvenile diabetes, Goodpasture's syndrome, pemphigoid, sympathetic ophthalmia, phacoemulsifying uveitis, autoimmune hemolytic anemia, idiopathic leukopenia, primary biliary cirrhosis, chronic active hepatitis, cryptogenic cirrhosis, ulcerative colitis, Sjogren's syndrome, scleroderma, Wegener's granulomatosis, polymyositis, dermatomyositis, discoid lupus or systemic lupus erythematosus.
[0092] In the present invention, the term “inflammatory disease” refers to a disease caused by an inflammatory cytokine (inflammatory cytokine) such as TNF-α, IL-1, IL-6, prostaglandin, leukotriene or NO secreted from immune cells such as macrophages by excessively stimulating the immune system due to harmful stimuli such as inflammatory factors or radiation exposure. The inflammatory disease of the present invention may include, but is not limited to, insulin-dependent diabetes, eczema, allergy, atopic dermatitis, acne, atopic rhinitis, pulmonary inflammation, allergic dermatitis, chronic sinusitis, contact dermatitis, seborrheic dermatitis, gastritis, gout, gouty arthritis, ulcer, chronic bronchitis, ulcerative colitis, ankylosing spondylitis, sepsis, vasculitis, bursitis, temporal arteritis, solid tumor, arteriosclerosis, obesity, viral infection, or nonalcoholic steatohepatitis.
[0093] The term “neurodegenerative disease” in the present invention refers to abnormalities in motor control ability, cognitive function, perception function, sensory function, and autonomic nervous system function due to a decrease or loss of nerve cell function, and is mainly classified by clinical characteristics and divided based on major symptoms and affected areas. The neurodegenerative disease of the present invention may include, but is not limited to, Alzheimer’s disease, frontotemporal dementia, Lewy dementia, corticobasal degeneration, Parkinson’s disease, multiple system atrophy, Huntington’s disease, supranuclear palsy, Lou Gehrig’s disease, primary lateral sclerosis, or spinal muscular atrophy.
[0094]
[0095] The term "prevention" as used in the present invention refers to any action that suppresses or delays a MyD88-related disease by administering a pharmaceutical composition comprising the peptide or the fusion peptide. In addition, the term "treatment" as used in the present invention refers to any action that improves or completely cures the symptoms of a MyD88-related disease by administering a pharmaceutical composition comprising the peptide or the fusion peptide.
[0096] The pharmaceutical composition for preventing or treating a MyD88-related disease according to the present invention may contain a pharmaceutically effective amount of the peptide or the fusion peptide alone, or may contain one or more pharmaceutically acceptable carriers, excipients, or diluents. The pharmaceutically effective amount herein refers to an amount sufficient to prevent, improve, and treat symptoms of a MyD88-related disease.
[0097] The term “pharmaceutically acceptable” as used herein refers to a composition that is physiologically acceptable and does not typically cause allergic reactions such as gastrointestinal upset or dizziness or similar reactions when administered to humans. Examples of the carrier, excipient, and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, and preservatives may be additionally included.
[0098] The term “carrier” refers to a substance that facilitates the addition of a compound into cells or tissues.
[0099] The term “diluent” is defined as a substance that not only stabilizes the biologically active form of the target compound, but also dilutes it in water to dissolve the compound.
[0100] In addition, the composition of the present invention may include at least one known effective ingredient having a therapeutic effect on a MyD88-related disease together with the peptide or the fusion peptide.
[0101] The composition of the present invention can be formulated using methods known in the art to provide rapid, sustained, or delayed release of the active ingredient after administration to a mammal, including a human. The formulation can be in the form of a powder, granule, tablet, emulsion, syrup, aerosol, soft or hard gelatin capsule, sterile injectable solution, sterile powder, patch (nano patch, hydrogel patch), or microneedle.
[0102] The composition of the present invention can be administered through various routes including orally, transdermally, subcutaneously, intravenously or intramuscularly, and the dosage of the active ingredient can be appropriately selected depending on various factors such as the route of administration, the patient's age, sex, weight and severity of the condition, and the composition according to the present invention can be administered in combination with a known compound having an effect of preventing, improving or treating symptoms of a MyD88-related disease.
[0103]
[0104] In another aspect, the present invention relates to a cosmetic composition for preventing or improving a MyD88-related disease comprising the peptide or the fusion peptide.
[0105] The description of the peptide or fusion peptide in the cosmetic composition of the present invention may be applied in accordance with the above description.
[0106] In the cosmetic composition of the present invention, the MyD88-related disease may be characterized as an autoimmune disease, an inflammatory disease, or a neurodegenerative disease, and preferably, may be characterized as an autoimmune disease, an inflammatory disease, or a neurodegenerative disease that can be prevented or improved by the cosmetic composition, such as psoriasis, eczema, allergy, atopic dermatitis, acne, allergic dermatitis, contact dermatitis, or seborrheic dermatitis, but is not limited thereto.
[0107] The term "improvement" of the present invention means any act that improves or benefits the condition of a MyD88-related disease by using a peptide or fusion peptide according to the present invention.
[0108] When the composition of the present invention is manufactured as a cosmetic composition, it may include the peptide or components commonly used in cosmetic compositions in addition to the peptide as an active ingredient, and may include, for example, conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, and carriers.
[0109] In the present invention, the cosmetic composition may be manufactured into any formulation commonly manufactured in the art, and may be formulated into, for example, a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powder foundation, an emulsion foundation, a wax foundation, and a spray, but is not limited thereto. More specifically, the cosmetic composition may be manufactured into a formulation such as a nourishing cream, an astringent toner, an emollient toner, a lotion, an essence, a nourishing gel, or a massage cream.
[0110] When the formulation of the above cosmetic composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, gum tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.
[0111] When the formulation of the above cosmetic composition is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether may be additionally included.
[0112] When the formulation of the above cosmetic composition is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
[0113] When the formulation of the above cosmetic composition is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used as a carrier component.
[0114] When the formulation of the above cosmetic composition is a surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester may be used as a carrier component. In the present invention, the cosmetic composition may be formulated by stabilizing the peptide or fusion peptide by containing it inside a nanoliposome. By incorporating the above peptide or fusion peptide into the nanoliposome, the components of the peptide or fusion peptide are stabilized, thereby resolving problems such as precipitation and deformation during formulation, and increasing the solubility and percutaneous absorption rate of the components, thereby maximizing the efficacy expected from the peptide or fusion peptide.
[0115] The cosmetic composition of the present invention may also be in the form of a polymer gel or microneedles made of a polymer, wherein the polymer is starch, cellulose ether, cellulose carboxymethylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, alginate, carrageenan, hyaluronic acid and derivatives thereof, polyacrylic acid, polysulfonate, and the like.
[0116]
[0117] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.
[0118]
[0119] Example 1: Materials and Methods
[0120] Example 1-1: Peptide design, optimization, and synthesis
[0121] To design peptides that can bind to MyD88, the Protein Data Bank (PDB) files for MyD88 (PDB ID: 7BEQ) and MAL (PDB ID: 5UZB) were downloaded and prepared for analysis by removing all missing residues, gaps, or structural issues. PyRosetta (Sidhartha Chaudhury, et al., PyRosetta:Bioinformatics.2010 Mar 1;26(5):689-9), a Python-based protein design software package, was used for peptide design and optimization. The interface region of MyD88 and interacting proteins were analyzed using PyRosetta's protein-protein coupling capabilities, which predict potential binding orientations and interactions between proteins. Suitable peptide templates were selected using the PyRosetta fragment insertion method (Jianyi Yang, et al., Proc Natl Acad Sci US A. 2020 Jan 21; 117(3): 1496-1503) from existing databases or through de novo structure generation. A set of peptide conformations was generated from the selected template structures, allowing mutations, insertions, or deletions. Undesirable conformations were filtered out through energy minimization and a scoring function. Optimal peptides were selected and refined through repacking, minimization, and side-chain optimization, and the scoring function was used to evaluate their energy and stability (Rebecca F Alford, et al., J Chem Theory Comput. 2017 Jun 13; 13(6): 3031-3048). The most promising peptide structures were selected for experimental validation based on their structural energy, stability, and compatibility with the MyD88 protein structure.
[0122] Alanine scanning was used to design potent derivatives of experimentally effective peptides. Each residue in the initial peptide was mutated to alanine, one at a time, while the remaining residues remained unchanged. To identify residue(s) essential for peptide stability and function, the energy of the mutant peptides was evaluated using PyRosetta's scoring function. These critical residues were mutated to other amino acids, and new peptides with altered properties were designed. To identify the most promising candidates, the designed peptides were scored for energy and stability using PyRosetta's scoring function. The selected peptides were further refined through repacking, minimization, and side-chain optimization, and then finally evaluated for energy and stability. To facilitate intracellular delivery, the CPP penetratin (RQIKIWFQNRRMKWKK (SEQ ID NO: 12)) was fused to the N-terminus of the peptide (D Derossi, et al., Journal of Biological Chemistry, 1994 Apr 8; 269(14): 10444-50). The peptide was synthesized by Peptron (Daejeon, Korea) with a purity of >90%, and its molecular weight was determined using liquid chromatography-mass spectrometry.
[0123]
[0124] Example 1-2: Chemicals and Reagents
[0125] IL-1β protein was purchased from Bio-Techne (Lille, France). Lipopolysaccharide (LPS; Escherichia coli 0111: B4) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Pam3CSK4, poly(I:C), imiquimod (IMQ), resiquimod (R848), and CpG oligodeoxynucleotide (CpG-ODN) were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). FSL-1 was purchased from InvivoGen (San Diego, CA, USA).
[0126] Antibodies against phospho-(p-)p65, p-JNK, JNK, ERK, p-p38, p38, and Iκ-βα were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA), and antibodies against p-ERK and β-actin were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).
[0127]
[0128] Example 1-3: Dissolution of peptides
[0129] A 10 mM stock solution was prepared by dissolving the peptide in sterile water and frozen at -20°C until use. MyDIP2 and MyDIP2-4 were 98% and 99% pure, respectively. For in vivo analysis of psoriasis and EAE, MyDIP2-4 was dissolved in phosphate-buffered saline (PBS). The control and disease groups were administered the same solution.
[0130]
[0131] Example 1-4: Cell culture
[0132] THP-1 and RAW 264.7 cells (ATCC, Manassas, VA, USA) were cultured in Roswell Park Memorial Institute (RPMI) medium and Dulbecco's modified Eagle medium (DMEM), respectively, supplemented with 10% fetal bovine serum (FBS), 4 mM L-glutamine, 1 mM sodium pyruvate, 100 units / ml penicillin, and 0.1 mg / ml streptomycin at 37°C in 5% CO2. Monocytic THP-1 cells were differentiated into macrophages by treatment with 80 nM phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) for 24 h. Cells were cultured in a humidified incubator (Thermo Fisher Scientific, Inc.) at 37°C with 5% CO2, and the medium was changed every 18 h.
[0133]
[0134] Example 1-5: Measurement of macrophage viability
[0135] To evaluate the cytotoxic effect of the peptide on mouse and human macrophages, RAW 264.7 cells and THP-1-derived macrophages were seeded at 5 × 10 in 96-well plates (BD Biosciences, San Jose, CA, USA), respectively. 4 / well and 2×10 5 / well and cultured overnight at 37°C in a humidified incubator. Cells were treated with the corresponding peptide concentrations for 24 h, and viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich). After 24 h of treatment, the medium was removed, 100 μL MTT solution was added to each well, and the plates were incubated at 37°C for 3 h. The MTT solution was then gently suctioned out, 100 μL dimethyl sulfoxide was added to each well, and the plates were gently shaken to dissolve the tetrazolium dye, and then incubated again at 37°C for 30 min. Relative cell viability was calculated by measuring the absorbance at 570 nm, and the untreated control group was designated as a relative viability of 100%. Cell viability in different groups was calculated by comparing it with the corresponding values in the control group.
[0136]
[0137] Example 1-6: Enzyme-linked immunosorbent assay (ELISA)
[0138] To evaluate the inhibitory effect of the peptide on cytokine secretion in response to various stimuli, RAW 264.7 cells and THP-1-derived macrophages were seeded at 5 × 10 in 96-well plates (BD Biosciences), respectively. 4 / well and 2×10 5 / well and cultured overnight. IL-6 secretion was assessed 24 h after treatment using a mouse IL-6 ELISA kit (Invitrogen). Tumor necrosis factor (TNF)-α production was assessed 4 h after treatment using a mouse TNF alpha ELISA kit (Invitrogen) according to the manufacturer's instructions. For THP-1-derived macrophages, TNF-α and IL-6 production were measured using human TNF-α and IL-6 ELISA kits (Invitrogen), respectively. Absorbance was measured at the appropriate wavelength using a microplate spectrophotometer system (Synergy HTX Multimode Reader, BioTek Instruments; Winooski, VT, USA).
[0139]
[0140] Example 1-7: Protein quantification and Western blot analysis
[0141] Mammalian Protein Extraction Reagent (M-PER, Thermo Fisher Scientific, Inc.) was used for total protein extraction, and a bicinchoninic acid (BCA) assay kit (Sigma-Aldrich) was used to assess protein concentration. Western blot analysis, including gel electrophoresis and transfer, was performed using the Mini-PROTEAN Tetra Cell and Mini Trans-Blot Electrophoretic Transfer Cell System (Bio-Rad Laboratories, Hercules, CA, USA). The membrane was incubated overnight at 4°C with antibodies to p-p65, p-JNK, JNK, p-ERK, ERK, p-p38, p38, IκBα, and β-actin at a 1:1000 dilution. The membrane was washed vigorously with PBS containing 0.1% Tween 20 (PBST, PBS + 0.1% Tween 20) and incubated with peroxidase-conjugated anti-mouse or anti-rabbit IgG antibody (1:1000) for 2 h. Proteins were detected with SuperSignal West Pico ECL solution (Thermo Fisher Scientific, Inc.) and visualized with a ChemiDoc Touch Imaging System (Bio-Rad Laboratories).
[0142]
[0143] Example 1-8: Animal Experiment
[0144] Example 1-8-1: Evaluation of the efficacy of MyDIP2-4 in an experimental autoimmune encephalomyelitis (EAE) model
[0145] (1) Mouse
[0146] Eight-week-old female C57BL / 6 (B6) mice (Orient Bio, Korea) were maintained in a specific pathogen-free environment on a standard laboratory ad libitum diet. All experiments were approved by the Animal Care and Use Committee of the Korea Institutional Animal Care and Use Committee (Endic Approval No. I2022111 (EAE) and I2022053-3 (Psoriasis), Hwaseong, Korea) and performed in accordance with relevant guidelines and regulations.
[0147]
[0148] (2) EAE induction and drug administration
[0149] According to the manufacturer's protocol, Hooke Kit (MOG 35-55 EAE was induced in mice using complete Freund's adjuvant (CFA) Emulsion PTX (Hooke Laboratories, LLC, Lawrence, MA, USA). Mice were immunized subcutaneously with myelin oligodendrocyte glycoprotein emulsified in complete Freund's adjuvant. Pertussis toxin (110 ng) was injected intraperitoneally at the time of immunization and 24 hours later. Dimethyl fumarate (100 mg / kg), a positive control, was administered orally, and MyDIP2-4 peptide was administered intraperitoneally at a dose of 40 mg / kg once daily from day 2 until the day of sacrifice.
[0150]
[0151] (3) Behavioral assessment
[0152] Mice were weighed and examined daily, and EAE symptoms were assessed using a standard scoring system: 0–6: 0, no disability; 1, limp tail; 2, limp tail and hind limb paralysis; 3, hind limb paralysis of one or more; 4, complete hind limb and hind trunk paralysis; 5, hind trunk paralysis and forelimb paralysis; and 6, death. Blood was collected from animals for cytokine analysis after euthanasia.
[0153]
[0154] Example 1-8-2: Evaluation of the efficacy of MyDIP2-4 in an imiquimod-induced psoriasis model
[0155] (1) Mouse
[0156] Six-week-old female C57BL / 6 mice (Orient Bio, Seongnam, Korea) were housed under specific pathogen-free conditions on a standard laboratory ad libitum diet. Animal experiments related to psoriasis were approved by the Animal Care and Use Committee of the Korean Institutional Animal Care and Use Committee (Endic Approval No. I2022111 (EAE) and I2022053-3 (Psoriasis), Hwaseong, Korea) and performed in accordance with relevant guidelines and regulations.
[0157]
[0158] (2) Induction and drug treatment of IMQ-induced psoriasis
[0159] Disease was induced by topical application of Aldara cream (Donga ST; Seoul, Korea) containing 5% imiquimod to the backs of 6-week-old female C57BL / 6 mice for 5 consecutive days. MyDIP2-4 was administered intraperitoneally at doses of 5 and 20 mg / kg. Dexamethasone (Sigma-Aldrich; cat. No. D1756) was administered orally at a dose of 10 mg / kg as a positive control. After 5 days, the mice were sacrificed under respiratory anesthesia, and skin lesions were collected for histological examination.
[0160]
[0161] (3) Evaluation of psoriasis site and severity index (PASI)
[0162] An objective scoring system was developed to quantify the severity of back skin inflammation, based on the PASI scoring system, a widely used clinical tool for assessing psoriasis severity. Factors such as erythema, scaling, wrinkles, and thickness were individually assessed on a scale from 0 to 4: 0, none; 1, mild; 2, moderate; 3, significant; and 4, very pronounced. Erythema, scaling, and thickness were graded under the careful supervision of a trained investigator. The cumulative score (erythema + scaling + thickness score, scaled from 0 to 12) represents the severity of psoriasis symptoms.
[0163]
[0164] (4) H&E (hematoxylin and eosin) staining and immunohistochemistry (IHC)
[0165] Skin tissues were excised, the upper layer was fixed in neutral formalin, and then H&E staining and IHC were performed. The epidermal thickness of the skin tissues was measured using H&E staining. IL-17, KI-67, and IL-23 levels were measured using IHC with the aid of antibodies to IL-17A (Thermo Fisher Scientific; cat. No. PA5-79470), KI-67 (Cell Signaling; cat. No. 12202), and IL-23 (Novus Biologicals; cat. No. NBP1-76697).
[0166]
[0167] Example 1-9: Surface plasmon resonance (SPR) analysis
[0168] The biophysical interaction between MyDIP2-4 and MyD88 was evaluated using SPR analysis on an iMSPR-mini system (icluebio, Seongnam, Korea). MyD88 protein was immobilized on the surface of a nitrilotriacetic acid (NTA) sensor chip at a concentration of 50 μg / mL. MyDIP2-4 was injected into the MyD88-binding chip at various concentrations ranging from 0.8 to 12.8 μM (dissolved in PBS) at a flow rate of 50 μL / min. PBS was used as the running buffer and injected into the empty channel as a reference. Experiments were performed twice using freshly prepared reagents, and data were analyzed using TraceDrawer software (Ridgeview Instruments; Uppsala, Sweden).
[0169]
[0170] Example 1-10: Statistical Analysis
[0171] All experiments were randomized and blinded. All experiments were performed independently at least three times, and the data were analyzed using GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA, USA) using a two-tailed t-test or one-way analysis of variance (ANOVA).
[0172]
[0173] Example 2: Identification of MyDIP2 as an Inhibitor of MyD88-Mediated Signaling
[0174] MyD88 plays a crucial role in activating the immune response and recognizes pathogenic microorganisms and danger signals through interactions with proteins such as TIRAP, TLR4, and IRAK4. As previously demonstrated, disrupting the TIR-TIR domain interaction of MyD88 through targeted substitution of specific residues can disrupt downstream signaling and potentially treat autoimmune diseases (Thomas Ve et al., Nat Struct Mol Biol. 2017 Sep;24(9):743-751). Using the PyRosetta program, we designed peptides (Figure 1) that targeted this domain and disrupted the interaction, and their activity against MyD88 was detected by LPS-induced activation of TLR4. The corresponding peptides and their interaction interfaces are shown in Table 2. LPS activates NF-κβ via MyD88-dependent signaling, leading to the secretion of proinflammatory cytokines, including TNF and IL-6 (Hongli Zhang, et al., Food and Chemical Toxicology, 2021 Jan;147:111915). When tested in response to LPS stimulation, MyDIP1 and MyDIP2 significantly suppressed IL-6 secretion, whereas only MyDIP2 significantly downregulated TNF-α secretion in response to LPS stimulation. Thus, among all peptides tested in response to LPS stimulation, MyDIP2 exhibited the greatest inhibition of LPS-mediated TNF-α and IL-6 activation in mouse macrophages (RAW 264.7 cells) (Figures 2a and 2b). CPP has no inhibitory effect on LPS-induced TNF-α secretion (Masaud Shah, et al., Biomaterials. 2020 Jul;245:119974). After 24 hours of treatment with each peptide, RAW 264.The toxicity of the peptide was evaluated at concentrations ranging from 1 to 50 μM using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 7 cells (Fig. 2c).
[0175] The inhibitory effect of MyDIP2 on all TLR ligands except TLR3 was evaluated based on the function of MyD88 as an adapter protein in all TLR-mediated signaling pathways. MyDIP2 inhibited TNF-α secretion in response to all tested TLRs, including TLR1 / 2, TLR2 / 6, TLR5, TLR7, TLR7 / 8, and TLR9, except TLR3. This suggests that MyDIP2 functions as an inhibitor of MyD88, which engages all TLRs except TLR3 (Fig. 2d). To enhance the inhibitory potency of MyDIP2, the peptide was further modified to design four additional peptides. The cytotoxicity of the four peptides was tested at a concentration of 50 μM using the MTT assay, and their efficacy against LPS (100 ng / ml) was tested at 20 μM using ELISA. The data revealed that all four peptides exhibited superior TNF-α inhibitory activity compared to MyDIP2. Among the tested peptides, MyDIP2-4 exhibited the highest potency. MyDIP2-4 was not cytotoxic to mouse macrophages (Figures 3a and 3b).
[0176]
[0177]
[0178] Example 3: Inhibitory effect of MyDIP2-4 on MyD88-mediated TLR activation and cytokine secretion in mouse macrophages
[0179] To determine the effect of MyDIP2-4 on RAW 264.7 cells, we examined the effect of MyDIP2-4 on IL-6 secretion. Cells were pretreated with various doses of MyDIP2-4 and then treated with LPS. IL-6 levels were quantified by ELISA. MyDIP2-4 significantly inhibited LPS-mediated IL-6 secretion (Fig. 3e). IC 50 The values were calculated by measuring the levels of TNF-α secreted from RAW 264.7 cells in response to LPS stimulation. IC of MyDIP2-4 in response to LPS stimulation 50 The value was 2.6 μM (Fig. 3c and Fig. 3d).
[0180] Since MyD88 is involved in signaling of multiple TLRs, the effect of MyDIP2-4 on TNF-α secretion levels in RAW 264.7 cells in response to different ligands, including Pam3CSK4 (TLR1 / 2), FSL-1 (TLR2 / 6), Poly(I:C) (TLR3), flagellin (TLR5), resiquimod (R848, TLR7 / 8), TL8 (TLR8), or CpG-ODN (TLR9), was measured by ELISA. Significant inhibition of TLR signaling was observed for all ligands (Fig. 3g).
[0181]
[0182] Example 4: Inhibitory effect of MyDIP2-4 on TLR7-dependent NF-κB signaling and MAPKs expression
[0183] To determine the effects of MyDIP2-4 on the protein expression of NF-κB and MAPKs, Western blot analysis was performed. MyDIP2-4 was found to significantly downregulate phospho p-65 expression and inhibit the degradation of IK-Bα. Furthermore, MyDIP2-4 inhibited phosphorylation of MAPKs, including ERK, JNK, and p-p38 (Fig. 3f).
[0184]
[0185] Example 5: Downregulation of TLR / IL-1R-mediated signaling by MyDIP2-4 in human macrophages
[0186] The effects of MyDIP2 and MyDIP2-4 on THP-1-derived macrophages were evaluated. The inhibitory effects of different concentrations of MyDIP2-4 on LPS-stimulated THP-1-derived macrophages were evaluated. ELISA results showed that MyDIP2-4 inhibited TNF-α secretion in THP-1-derived macrophages more effectively than MyDIP2 (Fig. 4b and 4c). To investigate the effect of MyDIP2-4 on IL-1R signaling, TNF-α secretion was assessed in THP-1-derived macrophages pretreated with MyDIP2-4 peptide followed by IL-1β protein treatment. MyDIP2-4 efficiently inhibited IL-1R signaling in THP-1-derived macrophages (Fig. 4d).
[0187] To confirm the specificity of MyDIP2-4, we measured IL-1β levels as a consequence of NLRP3 activation following nigericin treatment. To this end, PMA-differentiated THP-1 cells were primed with LPS (a TLR4 ligand), treated with MyDIP2-4 peptide, and then NLRP3 was activated with nigericin. While MyDIP2-4 was found to downregulate TNF-α in response to LPS, no effect was observed on nigericin-activated IL-1β levels (Fig. 4e).
[0188]
[0189] Example 6: Myelin Oligodendrocyte Glycoprotein (MOG) 35-55 )-induced EAE effects of MyDIP2-4
[0190] To investigate the therapeutic potential of MyDIP2-4 on EAE progression, MOG in CFA 35-55Mice were immunized with peptides and administered pertussis toxin once on day 0 and again 24 hours later. MyDIP2-4 (40 mg / kg) or dimethyl fumarate (DMF, 100 mg / kg) was administered intraperitoneally once daily. Onset of disease was observed on day 6. Mouse body weights and EAE clinical scores were recorded three times a week: days 0, 2, 5, 7, 9, 12, 14, 16, 19, and 21. As a result, MyDIP2-4-treated mice showed no difference in body weight compared to DMF-treated mice (Fig. 4i). On day 21, DMF reduced clinical scores compared to MyDIP2-4 (Fig. 4h). In contrast, MyDIP2-4 significantly suppressed IL-6 and IFN-γ cytokine secretion (Figs. 4l to 4m).
[0191]
[0192] Example 7: Evaluation of the therapeutic potential of MyDIP2-4 in IMQ-induced psoriasis.
[0193] To establish an IMQ-induced psoriasis model, Aldara cream containing 5% imiquimod was topically applied to the backs of 6-week-old female C57BL / 6 mice for 5 consecutive days. Dexamethasone, a positive control, was administered orally, and MyDIP2-4 was administered intraperitoneally. The doses of MyDIP2-4 were 5 mg / kg and 20 mg / kg, and the dose of dexamethasone was 10 mg / kg. PBS was used as a vehicle control. The data suggested that progressive symptoms could be observed in the IMQ-treated group (Fig. 5c). The degree of epidermal infiltration was significantly reduced in the dexamethasone-treated group, but not in the MyDIP2-4-treated group (Fig. 5e). Immunohistochemical data suggested that the proportion of KI-67-positive cells was significantly reduced in both the MyD88- and dexamethasone-treated groups. Additionally, MyDIP2-4 significantly reduced IL-23 levels (Fig. 5f). Dexamethasone and MyDIP2-4 did not suppress IL-17 expression (Fig. 5f).
[0194]
[0195] Example 8: Confirmation of biophysical interactions between MyDIP2-4 and MyD88 using SPR analysis.
[0196] SPR technology was used to evaluate the biophysical interaction between the MyDIP2-4 peptide and the MyD88 protein. The SPR analysis involved immobilizing the MyDIP2-4 protein on the surface of the sensor chip and then flowing the MyDIP2-4 peptide at various concentrations. The SPR sensorgrams showed that the MyDIP2-4 peptide bound to the immobilized MyD88 protein in a concentration-dependent manner (Fig. 4f). In addition, the rate constants for the association (Ka) and dissociation (Kd) for the MyDIP2-4-MyD88 interaction were measured, and were 3.70 M , respectively. -1 s -1 and 1.37 × 10 -7 s -1Overall, the data support the notion that the MyDIP2-4 peptide exhibits a strong and dose-dependent interaction with human MyD88 protein.
[0197]
[0198] In the present invention, candidate peptides targeting MyD88 were demonstrated to be potent inhibitors of TLR- and IL-1R-mediated signaling pathways through in vitro and in vivo experiments. Peptides offer better efficacy, safety, selectivity, and potential than small molecules and chemicals, making them a promising option for therapeutic development. Among the candidates targeting MyD88, MyDIP2-4 (MyD88 inhibitory peptide 2-4) appears to be the most effective and potent peptide, and thus MyDIP2-4 may be an effective therapeutic agent for autoimmune complications caused by pathogens or environmental factors.
[0199]
[0200] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
[0201]
[0202] Electronic file attached.
Claims
1. A peptide represented by any one amino acid sequence selected from the group consisting of sequence numbers 1 to 11.
2. A peptide according to claim 1, characterized in that the peptide inhibits MyD88-mediated signaling and thereby inhibits TLR and IL-1R-mediated signaling pathways.
3. A fusion peptide comprising the peptide of paragraph 1 and a cell-penetrating peptide (CPP).
4. A MyD88 inhibitor comprising the peptide of claim 1 or the fusion peptide of claim 3.
5. A pharmaceutical composition for preventing or treating a MyD88-related disease, comprising the peptide of paragraph 1 or the fusion peptide of paragraph 3.
6. A pharmaceutical composition according to claim 5, wherein the MyD88-related disease is an autoimmune disease, an inflammatory disease, or a neurodegenerative disease.
7. In paragraph 6, the pharmaceutical composition is characterized in that the autoimmune disease is psoriasis, rheumatoid arthritis, psoriatic arthritis, experimental autoimmune arthritis, asthma, Crohn's disease, multiple sclerosis, experimental autoimmune encephalomyelitis, myasthenia gravis, thyroiditis, experimental uveitis, Hashimoto's thyroiditis, primary myxedema, thyrotoxicosis, pernicious anemia, autoimmune atrophic gastritis, Addison's disease, premature menopause, male infertility, juvenile diabetes, Goodpasture's syndrome, pemphigoid, sympathetic ophthalmia, phacoemulsifying uveitis, autoimmune hemolytic anemia, idiopathic leukopenia, primary biliary cirrhosis, chronic active hepatitis, cryptogenic cirrhosis, ulcerative colitis, Sjogren's syndrome, scleroderma, Wegener's granulomatosis, polymyositis, dermatomyositis, discoid lupus or systemic lupus erythematosus. Composition.
8. A pharmaceutical composition according to claim 6, characterized in that the inflammatory disease is insulin-dependent diabetes, eczema, allergy, atopic dermatitis, acne, atopic rhinitis, pulmonary inflammation, allergic dermatitis, chronic sinusitis, contact dermatitis, seborrheic dermatitis, gastritis, gout, gouty arthritis, ulcer, chronic bronchitis, ulcerative colitis, ankylosing spondylitis, sepsis, vasculitis, bursitis, temporal arteritis, solid cancer, arteriosclerosis, obesity, viral infection, or nonalcoholic steatohepatitis.
9. A pharmaceutical composition according to claim 6, characterized in that the neurodegenerative disease is Alzheimer's disease, frontotemporal dementia, Lewy dementia, corticobasal degeneration, Parkinson's disease, multiple system atrophy, Huntington's disease, supranuclear palsy, Lou Gehrig's disease, primary lateral sclerosis, or spinal muscular atrophy.
10. A cosmetic composition for preventing or improving a MyD88-related disease, comprising the peptide of paragraph 1 or the fusion peptide of paragraph 3.
11. A cosmetic composition according to claim 10, characterized in that the MyD88-related disease is an autoimmune disease, an inflammatory disease, or a neurodegenerative disease.
Citation Information
Patent Citations
Peptides for inhibiting toll-like receptors (TLRs) and pharmaceutical compositions containing the same
JP2020518679A
Treatment of age-related macular degeneration using RNA complexes that target myd88 or TLR3
KR1020180071362A
Method of treating diseases associated with MYD88 pathways using crispr-GNDM system
US20210260170A1
